Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL585066 | 0.92 | CNR2 (0.53) | CNR2CNR1 | |
| Hydrochloric Acid SCHEMBL4966250 | 0.91 | CNR2 (0.53) | CNR2CNR1 | |
| SCHEMBL585121 | 0.91 | CNR2 (0.66) | CNR2CNR1 | |
| SCHEMBL4966376 | 0.87 | CNR2 (0.53) | CNR2CNR1 | |
| SCHEMBL1608436 | 0.87 | CNR2 (0.55) | CNR2CNR1 | |
| Hydrochloric Acid SCHEMBL4969009 | 0.86 | CNR2 (0.52) | CNR2CNR1 | |
| SCHEMBL4966152 | 0.85 | CNR2 (0.54) | CNR2CNR1 | |
| Hydrochloric Acid SCHEMBL4968470 | 0.85 | CNR2 (0.53) | CNR2CNR1 | |
| SCHEMBL1609675 | 0.84 | CNR2 (0.57) | CNR2CNR1 | |
| SCHEMBL4967092 | 0.83 | CNR2 (0.52) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797077-B1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF I | ASTRAZENECA AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| EP-1797077-B1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF I | ASTRAZENECA AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| US-20090221657-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221657-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221657-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-7550495-B2 | Compounds, compositions containing them, preparation thereof and uses thereof I | ASTRAZENECA AB (SE) | 2009-06-23 | — | — | US | disclosed |
| US-7550495-B2 | Compounds, compositions containing them, preparation thereof and uses thereof I | ASTRAZENECA AB (SE) | 2009-06-23 | — | — | US | disclosed |
| US-7550495-B2 | Compounds, compositions containing them, preparation thereof and uses thereof I | ASTRAZENECA AB (SE) | 2009-06-23 | — | — | US | disclosed |
| EP-1670770-B1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEROF AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| US-20070082899-A1 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | US | disclosed |
| US-20070082899-A1 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | US | disclosed |
| US-20070082899-A1 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | US | disclosed |
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | US | disclosed |
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | US | disclosed |
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | US | disclosed |
| US-20060264490-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | ASTRAZENECA AB (SE) | 2006-11-23 | — | — | US | disclosed |
| EP-1673369-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | AstraZeneca AB (SE) | 2006-06-28 | — | — | EP | disclosed |
| EP-1670770-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEROF AND USES THEREOF | AstraZeneca AB (SE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005030761-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030733-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEROF AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264490-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | F12, C1S, C1R | CNR2 83/4885CNR1 54/4885 |
| US-20070082899-A1 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | F12, H1-3, H1-4 | CNR2 697/4885CNR1 514/4885 |
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | RB1, CYP2C19, ADRB3 | CNR2 202/4885CNR1 182/4885 |
| US-20090221657-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | F12, C1S, C1R | CNR2 83/4885CNR1 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.